Biovaxys Technology Corp (BVAXF)

$0.12 +0.04 (43.03%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 20,600
Avg Vol 124,326
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 100%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

BioVaxys Technology Corp., a clinical-stage biotechnology company, engages in developing viral and oncology vaccine platforms and immuno-diagnostics. The company offers DPX immune educating technology platform and HapTenix neoantigen tumor cell construct platform for treating cancers, infectious diseases, antigen desensitization, and other immune diseases. It also provides Maveropepimut-S (MVP-S), which has completed phase IIb clinical trial for advanced Relapsed-Refractory Diffuse Large B Cell...

Industry: Biotechnology
Sector: Healthcare
Phone: 740-358-0555
Address:
146 Thirtieth Street, Suite 100, Etobicoke, Canada
Davidendz
Davidendz May. 13 at 6:52 PM
$BIOV.CSE $BVAXF Frustrating to see the CSE halt, but the core business keeps moving. Positive Phase 2 data in bladder & ovarian cancer, DPX platform validation, and OTC liquidity still available for shareholders outside Canada.
0 · Reply
ProfitWhisperer
ProfitWhisperer May. 13 at 2:48 PM
DPX peer reviewed in Nature. ASCO May 29. 2T Labs in vivo results due mid to late May. AI plus biology is already happening. $BIOV $BVAXF
0 · Reply
ProfitWhisperer
ProfitWhisperer May. 13 at 2:41 PM
BVAXF trading on OTC at 10 cents while CSE halt continues. 2T Labs in vivo DPX-mRNA results due mid to late May. May 31 filing target still on the table. $BVAXF
0 · Reply
ProfitWhisperer
ProfitWhisperer May. 12 at 4:43 PM
BVAXF moving on OTC while CSE halt is in effect. interesting timing. AI designed personalized cancer vaccines getting mainstream attention. Adiverna CEO led Sanofi mRNA COVID research, now applying same approach to DPX at 2T Labs. in vivo results expected mid to late May. $BVAXF
0 · Reply
FLArnot
FLArnot May. 12 at 2:30 AM
$BVAXF I am very positive on this company and especially their DPX technology. But when it comes to getting their financials in on time, this picture says it best.
0 · Reply
ProfitWhisperer
ProfitWhisperer May. 11 at 4:26 PM
AI designed personalized mRNA cancer vaccines are no longer theoretical. a data scientist used ChatGPT and AlphaFold to design a custom mRNA vaccine for his dog's cancer. tumor shrunk 75% in two months. Adiverna CEO Kalnin led Sanofi's mRNA COVID vaccine development. now applying AI designed mRNA sequences to DPX platform at 2T Labs in San Diego. in vivo results expected mid to late May. $BIOV $BVAXF https://finance.yahoo.com/news/mans-dog-riddled-tumors-dying-210500037.html
1 · Reply
NewMexicats
NewMexicats May. 11 at 4:14 PM
$BVAXF Kind of an interesting article concerning AI & personalized cancer vaccines: https://finance.yahoo.com/news/mans-dog-riddled-tumors-dying-210500037.html Recall that unpublished results from the Etherna testing of DPX mRNA were first revealed in September 2024 tweets promoting Dr Berd's presentation at the December 2024 Personalized Cancer Vaccine Conference in Boston. Now Adiverna/BioVaxys is testing DPX mRNA AI designed mRNA formulation at 2T Labs in San Diego. Results duplicating the 14 day Etherna should be available in mid to late May based on tweet regarding lipid delivery to 2T. If they are after longer term immune response that will obviously take an additional month or two. IMV work that was lost in the bankruptcy shuffle and in IMV last ditch year where they were solely devoted to MVP-S to conserve resources.
0 · Reply
ProfitWhisperer
ProfitWhisperer May. 11 at 4:04 PM
DMCL has been auditing BIOV through the IMV acquisition and all the complexity that came with it. switching auditors now resets the clock entirely. continuity is an asset. May 31 is the line. $BIOV $BVAXF
0 · Reply
ProfitWhisperer
ProfitWhisperer May. 11 at 4:00 PM
science keeps delivering. Nature published, ASCO May 29, Sanofi hat trick confirmed. admin side is the only thing between where we are and where this should be priced. May 31 has to hold. $BIOV $BVAXF
0 · Reply
ProfitWhisperer
ProfitWhisperer May. 11 at 3:55 PM
auditor continuity matters. switching firms mid-complexity resets the clock entirely. DMCL knowing the IMV acquisition history is an asset not a liability. $BIOV $BVAXF
0 · Reply
Latest News on BVAXF
No data available.
Davidendz
Davidendz May. 13 at 6:52 PM
$BIOV.CSE $BVAXF Frustrating to see the CSE halt, but the core business keeps moving. Positive Phase 2 data in bladder & ovarian cancer, DPX platform validation, and OTC liquidity still available for shareholders outside Canada.
0 · Reply
ProfitWhisperer
ProfitWhisperer May. 13 at 2:48 PM
DPX peer reviewed in Nature. ASCO May 29. 2T Labs in vivo results due mid to late May. AI plus biology is already happening. $BIOV $BVAXF
0 · Reply
ProfitWhisperer
ProfitWhisperer May. 13 at 2:41 PM
BVAXF trading on OTC at 10 cents while CSE halt continues. 2T Labs in vivo DPX-mRNA results due mid to late May. May 31 filing target still on the table. $BVAXF
0 · Reply
ProfitWhisperer
ProfitWhisperer May. 12 at 4:43 PM
BVAXF moving on OTC while CSE halt is in effect. interesting timing. AI designed personalized cancer vaccines getting mainstream attention. Adiverna CEO led Sanofi mRNA COVID research, now applying same approach to DPX at 2T Labs. in vivo results expected mid to late May. $BVAXF
0 · Reply
FLArnot
FLArnot May. 12 at 2:30 AM
$BVAXF I am very positive on this company and especially their DPX technology. But when it comes to getting their financials in on time, this picture says it best.
0 · Reply
ProfitWhisperer
ProfitWhisperer May. 11 at 4:26 PM
AI designed personalized mRNA cancer vaccines are no longer theoretical. a data scientist used ChatGPT and AlphaFold to design a custom mRNA vaccine for his dog's cancer. tumor shrunk 75% in two months. Adiverna CEO Kalnin led Sanofi's mRNA COVID vaccine development. now applying AI designed mRNA sequences to DPX platform at 2T Labs in San Diego. in vivo results expected mid to late May. $BIOV $BVAXF https://finance.yahoo.com/news/mans-dog-riddled-tumors-dying-210500037.html
1 · Reply
NewMexicats
NewMexicats May. 11 at 4:14 PM
$BVAXF Kind of an interesting article concerning AI & personalized cancer vaccines: https://finance.yahoo.com/news/mans-dog-riddled-tumors-dying-210500037.html Recall that unpublished results from the Etherna testing of DPX mRNA were first revealed in September 2024 tweets promoting Dr Berd's presentation at the December 2024 Personalized Cancer Vaccine Conference in Boston. Now Adiverna/BioVaxys is testing DPX mRNA AI designed mRNA formulation at 2T Labs in San Diego. Results duplicating the 14 day Etherna should be available in mid to late May based on tweet regarding lipid delivery to 2T. If they are after longer term immune response that will obviously take an additional month or two. IMV work that was lost in the bankruptcy shuffle and in IMV last ditch year where they were solely devoted to MVP-S to conserve resources.
0 · Reply
ProfitWhisperer
ProfitWhisperer May. 11 at 4:04 PM
DMCL has been auditing BIOV through the IMV acquisition and all the complexity that came with it. switching auditors now resets the clock entirely. continuity is an asset. May 31 is the line. $BIOV $BVAXF
0 · Reply
ProfitWhisperer
ProfitWhisperer May. 11 at 4:00 PM
science keeps delivering. Nature published, ASCO May 29, Sanofi hat trick confirmed. admin side is the only thing between where we are and where this should be priced. May 31 has to hold. $BIOV $BVAXF
0 · Reply
ProfitWhisperer
ProfitWhisperer May. 11 at 3:55 PM
auditor continuity matters. switching firms mid-complexity resets the clock entirely. DMCL knowing the IMV acquisition history is an asset not a liability. $BIOV $BVAXF
0 · Reply
Ventureville
Ventureville May. 11 at 1:08 PM
$BIOV.CSE $BVAXF easy to blame the auditor, but DMCL has been there long-term. Delays like this usually tie back to client-side changes, systems, integrations, plus big events like the IMV acquisition. Not always an audit issue, often complexity catching up. Key is getting filings done by May 31 so focus shifts back to the pipeline.
0 · Reply
Ventureville
Ventureville May. 8 at 6:57 PM
$BIOV.CSE $BVAXF the repeated audit delays are getting old. Same story around patents and legacy IMV complexities. At some point this stops being timing and starts being accountability. If May 31 slips again, management needs to seriously rethink the auditor situation. The science is there, admin side shouldn’t be the bottleneck.
1 · Reply
ProfitWhisperer
ProfitWhisperer May. 8 at 4:22 PM
three former Sanofi executives surrounding one platform. Tartaglia global vaccine head. Lievonen Sanofi Pasteur president. Kalnin mRNA research leader who worked on the Sanofi COVID vaccine, now leading DPX-mRNA work with 2T Labs. that network does not form by accident. $BIOV $BVAXF
2 · Reply
wheresdannynow
wheresdannynow May. 8 at 4:00 PM
Frustrating watching $BIOV.CSE $BVAXF deal with another halt while the underlying science keeps progressing. New MVP-S imaging + cancer data continue to reinforce the platform, but filing delays are clearly holding momentum back. This isn’t a tech problem, it’s an execution problem on the admin side. If management gets filings done by May 31, the focus shifts back to what matters, the pipeline. Names like $MRNA $BNTX didn’t get attention until the data forced it.
1 · Reply
NewMexicats
NewMexicats May. 8 at 1:13 PM
$BVAXF The Sanofi Connections *Jim Tartaglia - Biovaxys Board Member. Former Global Head of Development for Sanofi Vaccine *Mark Lievonen - Sona Nanotech Chairman of the Board. Former President of Sanofi Pasteur Canada. *Kirill Kalnin - CEO Adiverna. Former mRNA Research Leader for Sanofi Pasteur. Sona Nanotech is in collaboration with BioVaxys on its targeted tumor hyperthermia therapy and testing DPX adjuvant immune stimulating qualities with no cargo. Adiverna developed an AI formulation for mRNA which is currently being animal tested at 2T labs. This could provide additional proof that DPX is a better platform than Liquid Nanoparticles for mRNA - shelf/temperature stable, no leakage (side effects), longer lasting with additional immune boosting qualities.
0 · Reply
NewMexicats
NewMexicats May. 7 at 9:30 PM
$BVAXF I had posted previously about Kirill Kalnin, PhD having received innovation awards from Sanofi. He is the CEO of Adiverna and doing the AI mRNA work with 2T labs in San Diego. What I missed, or it was just added, is his resume on LinkedIn. See screenshot. He was mRNA Research Leader from 2018 to 2021 working on the Covid vaccine for Sanofi Pasteur in Cambridge, MA.
0 · Reply
ProfitWhisperer
ProfitWhisperer May. 7 at 4:38 PM
Zoetis missed on discretionary pet spending but SpayVac is immunocontraception not a discretionary vet visit. macro weakness doesn't directly hit that product category. meanwhile 2T Labs in vivo DPX-mRNA results could land around the same time financials are filed. $BVAXF
0 · Reply
Davidendz
Davidendz May. 7 at 4:26 PM
Man, brutal timing for $BIOV.CSE / $BVAXF DPX data looked genuinely promising, so this filing halt feels like momentum got cut short by paperwork. Hoping they get current fast, because the science was finally getting attention. $MRNA $BNTX #Biotech
1 · Reply
NewMexicats
NewMexicats May. 7 at 11:53 AM
$BVAXF Watching for the results of these studies at 2T Labs: "The DPX-mRNA vaccine collaboration with Adiverna continues to advance. We just shipped the completed GMP-grade custom lipid that is the structural foundation of DPX to 2T Labs, the San Diego-based CRO that is supporting the formulation work. In vivo challenge studies are now scheduled for upcoming weeks." https://x.com/i/status/2047337697686036689 Imho, if the in vivo results are positive, it validates the DPX platform as a viable alternative to traditional Lipid Nanoparticles (LNPs) for mRNA delivery. Combined with the Nature Imaging, DPX will be looking very attractive.
0 · Reply
FLArnot
FLArnot May. 6 at 6:15 PM
$BVAXF Personally the CSE halt doesn't trouble me, frustrating yes, but not troubling. Way to many positives happening with DPX right now. I just can't wait for them to have positive revenue and actually afford to bring some of this accounting in house. I would rather see them continue to operate VERY LEAN and have an occasional halt or MCTO than to to over extend. Compare their payroll numbers to others out there and you will see what I mean.
0 · Reply
ProfitWhisperer
ProfitWhisperer May. 6 at 5:16 PM
CSE halt is painful but the story isn't over. $BVAXF OTC still trading. halt lifts when annual filings land. May 31 target still on the table. how fast management delivers is the only thing that matters now. $BIOV $BVAXF
1 · Reply
ProfitWhisperer
ProfitWhisperer May. 6 at 5:14 PM
CIRO trading halt on $BIOV CSE. filing deficiency triggered the halt as expected with an active MCTO. $BVAXF OTC market still trading. this resolves when the annual filings land. May 31 target still on the table. watching for official company statement. $BIOV $BVAXF
0 · Reply